/CYBN.NE
CYBN.NE Stock - Cybin Inc.
Healthcare|BiotechnologyNEO
$9.79-1.11%
$0.11 (-1.11%) • Dec 22
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.69
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.76
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $10.77
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CYBN.NE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.69 – $9.89
TARGET (TP)$11.26
STOP LOSS$9.01
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.09
52W High$15.55
52W Low$6.95
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $864,000 |
| Gross Profit | N/A | $-424,000 | $-251,000 | $-168,000 | $200,000 |
| Gross Margin | N/A | N/A | N/A | N/A | 23.1% |
| Operating Income | $-143,147,000 | $-78,836,000 | $-54,943,000 | $-63,597,000 | $-31,035,000 |
| Net Income | $-113,137,000 | $-78,080,000 | $-47,490,000 | $-67,631,000 | $-32,220,000 |
| Net Margin | N/A | N/A | N/A | N/A | -3729.2% |
| EPS | $-0.61 | $-9.50 | $-0.26 | $-0.40 | $-12.16 |
Company Overview
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CYBN.NEBeat Rate
27%
Last 15 quarters
Avg Surprise
-54.7%
EPS vs Estimate
Beats / Misses
4/10
1 met exactly
Latest EPS
$-1.92
Q4 2025
EPS Surprise History
Q4 23
0.0%
$-0.05vs$-0.05
Q1 24
-125.0%
$-0.09vs$-0.04
Q1 24
No data
Q3 24
-42.9%
$-0.02vs$-0.01
Q4 24
-197.9%
$-2.86vs$-0.96
Q1 25
+48.5%
$-0.53vs$-1.03
Q3 25
-33.9%
$-1.46vs$-1.09
Q4 25
-141.4%
$-1.92vs$-0.80
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | $-0.80 | $-1.92 | -141.4% | ✗ MISS |
Q3 2025 | Jul 1, 2025 | $-1.09 | $-1.46 | -33.9% | ✗ MISS |
Q1 2025 | Feb 10, 2025 | $-1.03 | $-0.53 | +48.5% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.96 | $-2.86 | -197.9% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.01 | $-0.02 | -42.9% | ✗ MISS |
Q1 2024 | Mar 30, 2024 | — | $-1.07 | — | — |
Q1 2024 | Feb 14, 2024 | $-0.04 | $-0.09 | -125.0% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.05 | $-0.05 | 0.0% | = MET |
Q3 2023 | Aug 14, 2023 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | — | $-0.07 | — | — |
Q1 2023 | Feb 14, 2023 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | — | $-0.10 | — | — |
Q1 2022 | Feb 10, 2022 | $-0.09 | $-0.10 | -11.1% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.08 | $-0.11 | -37.5% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $-0.05 | $-0.09 | -80.0% | ✗ MISS |
Q1 2021 | Mar 31, 2021 | — | $-0.09 | — | — |
Q1 2021 | Feb 17, 2021 | $-0.03 | $-0.10 | -233.3% | ✗ MISS |
Q4 2020 | Nov 10, 2020 | — | $-0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about CYBN.NE
What is CYBN.NE's current stock price?
Cybin Inc. (CYBN.NE) is currently trading at $9.79 per share. The stock has moved -1.11% today.
What is the analyst price target for CYBN.NE?
No analyst price targets are currently available for this stock.
What sector is Cybin Inc. in?
Cybin Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NEO exchange.
What is CYBN.NE's market cap?
Cybin Inc. has a market capitalization of $0.24 billion, making it a small-cap company.
Does CYBN.NE pay dividends?
No, Cybin Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCRRX.TO
CareRx Corporation
$3.87
Mkt Cap: $0.2B
DR.TO
Medical Facilities Corporation
$15.48
Mkt Cap: $0.3B
EPRX.TO
Eupraxia Pharmaceuticals Inc.
$9.70
Mkt Cap: $0.3B
FRX.TO
Fennec Pharmaceuticals Inc.
$10.63
Mkt Cap: $0.3B
HBP.TO
Helix BioPharma Corp.
$2.29
Mkt Cap: $0.2B
JUSH.CN
Jushi Holdings Inc.
$0.76
Mkt Cap: $0.1B
MSCL.TO
Satellos Bioscience Inc.
$0.66
Mkt Cap: $0.1B
NGEN.V
NervGen Pharma Corp.
$6.85
Mkt Cap: $0.5B
PRN.TO
Profound Medical Corp.
$10.03
Mkt Cap: $0.3B
XLY.TO
Auxly Cannabis Group Inc.
$0.15
Mkt Cap: $0.2B
Explore stocks similar to CYBN.NE for comparison